Log In
BCIQ
Print this Print this
 

Anti-5T4 NDC

  Manage Alerts
Collapse Summary General Information
Company Ambrx Inc.
DescriptionAntibody-drug conjugate (ADC) targeting oncofetal antigen 5T4 that was developed using EuCode amino acid incorporation technology
Molecular Target Oncofetal antigen 5T4
Mechanism of ActionAntibody-drug conjugate
Therapeutic ModalityBiologic: Antibody-drug conjugate
Latest Stage of DevelopmentPreclinical
Standard Indication Cancer (unspecified)
Indication DetailsTreat cancer
Regulatory Designation
PartnerPfizer Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

0

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

06/19/2015

Undisclosed

Undisclosed

Undisclosed

Get a free BioCentury trial today